PDCD1 and head and neck squamous cell carcinoma: Because of the clinical efficacy and safety profile shown in the phase II trial, BURAN (NCT04338399), a phase III trial was undertaken in 483 patients with recurrent or metastatic HNSCC who showed progression after cisplatin or anti-programmed cell death protein 1 (PD1)-based treatment either as monotherapy or combination treatment.